| Literature DB >> 30080177 |
Changshan Wang1,2, Motohiko Oshima2, Daisuke Sato2, Hirotaka Matsui3, Sho Kubota4, Kazumasa Aoyama2, Yaeko Nakajima-Takagi2, Shuhei Koide2, Jun Matsubayashi5, Makiko Mochizuki-Kashio2, Takako Nakano-Yokomizo4, Jie Bai4, Toshitaka Nagao5, Akinori Kanai6, Atsushi Iwama2,7, Goro Sashida2,4.
Abstract
Early T cell precursor acute lymphoblastic leukemia (ETP-ALL) is a new pathological entity with poor outcomes in T cell ALL (T-ALL) that is characterized by a high incidence of loss-of-function mutations in polycomb repressive complex 2 (PRC2) genes. We generated a mouse model of ETP-ALL by deleting Ezh2, one of the PRC2 genes, in p53-null hematopoietic cells. The loss of Ezh2 in p53-null hematopoietic cells impeded the differentiation of ETPs and eventually induced ETP-ALL-like disease in mice, indicating that PRC2 functions as a bona fide tumor suppressor in ETPs. A large portion of PRC2 target genes acquired DNA hypermethylation of their promoters following reductions in H3K27me3 levels upon the loss of Ezh2, which included pivotal T cell differentiation-regulating genes. The reactivation of a set of regulators by a DNA-demethylating agent, but not the transduction of single regulator genes, effectively induced the differentiation of ETP-ALL cells. Thus, PRC2 protects key T cell developmental regulators from DNA hypermethylation in order to keep them primed for activation upon subsequent differentiation phases, while its insufficiency predisposes ETPs to leukemic transformation. These results revealed a previously unrecognized epigenetic switch in response to PRC2 dysfunction and provide the basis for specific rational epigenetic therapy for ETP-ALL with PRC2 insufficiency.Entities:
Keywords: Epigenetics; Hematology; Leukemias; Oncology; T cells
Mesh:
Substances:
Year: 2018 PMID: 30080177 PMCID: PMC6118644 DOI: 10.1172/JCI94645
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808